Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Lawrence, Karsh"'
Autor:
Lawrence Karsh, Sreenivas Adurthi, Rahul Aggarwal, Mark Linch, Dan Costin, Jingsong Zhang, Paul Monk, Stefani Corsi-Travali, Adedayo Adedoyin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/601b43f12be841d29a9b2623f23e1d29
Autor:
Neal Shore, Lawrence Karsh, Daniel Shevrin, James Symanowski, Daniel Lin, Jeff Turner, David Russell, Yi Song, James Spalding, Filipa Negreiro, David Penson
Publikováno v:
Journal of Urology. 209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61b0c971cf7d17d5c649156aba48ed00
https://doi.org/10.1097/ju.0000000000003257.05
https://doi.org/10.1097/ju.0000000000003257.05
Autor:
Lawrence Karsh, Andrew Meads, Madlen Malinowski, Douglas S. Scherr, Soumi Lahiri, Michael Vernia, Elyse Seltzer, David L. Morris, Sunil Raju, Neal D. Shore, Jennifer Linehan, Daniel Saltzstein, Steven Kester, Alexander Sankin, Arnold Cinman, K. Kent Chevli, Mark P. Schoenberg, Mark D. Tyson, Boris Friedman, Yaron Ehrlich, Karim Chamie, Andrew Trainer, Nimrod Gabai, Jay D. Raman, Angela B. Smith, Richard D’Anna, Brian Hu, William C. Huang, Max Kates
Publikováno v:
Journal of Urology. 207:61-69
Purpose Low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG IR NMIBC) is a recurrent disease, thus requiring repeated transurethral resection of bladder tumor under general anesthesia. We evaluated the efficacy and safety of UGN-102, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::445cacd01d9a79e6dbfd406bf2eef098
https://doi.org/10.1097/ju.0000000000002186
https://doi.org/10.1097/ju.0000000000002186
Autor:
Neal D. Shore, Arnulf Stenzl, Christopher Pieczonka, Zachary Klaassen, William J. Aronson, Lawrence Karsh, Charles J. Ryan, Jorge Ortiz, Shankar Srinivasan, Ateesha F. Mohamed, Frank Verholen
Publikováno v:
BJU internationalReferences.
To assess, the effect of darolutamide (a structurally distinct androgen receptor inhibitor) on urinary and bowel symptoms, using data from the phase III ARAMIS trial (NCT02200614) that showed darolutamide significantly reduced the risk of metastasis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5bdd8b73c898e747d4878f449d3f205
https://pubmed.ncbi.nlm.nih.gov/36087070
https://pubmed.ncbi.nlm.nih.gov/36087070
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alan Boyd, Tracy M. Downs, Brian R. Lane, Michael Woods, Brant A. Inman, Joseph Mashni, Gary D. Steinberg, Kirk A. Keegan, Alexander Sankin, Joseph E. Busby, Stephen A. Boorjian, Robert S. Svatek, Richard Philipson, Paul L. Crispen, Michael A. O’Donnell, Seth P. Lerner, Daniel J. Canter, Colin P.N. Dinney, Vikram M. Narayan, Yair Lotan, Tracey L. Krupski, Michael S. Cookson, Leonard G. Gomella, Ashish M. Kamat, David Sawutz, Lawrence Karsh, Michael B. Williams, F. Peter Treasure, Ruth Coll, Gennady Bratslavsky, Thomas J. Guzzo, Adam Luchey, Mehrdad Alemozaffar, Trinity J. Bivalacqua, Michael A. Poch, Jeffrey S. Montgomery, Badrinath R. Konety, Nigel Parker, Anne Schuckman, Seppo Ylä-Herttuala, Neal D. Shore, Gordon D. Brown, Gerald L. Andriole
Publikováno v:
The Lancet Oncology. 22:107-117
Summary Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2886c9be02be1fb7917e6d1dcffd8aad
https://doi.org/10.1016/s1470-2045(20)30540-4
https://doi.org/10.1016/s1470-2045(20)30540-4
Autor:
Charles G. Drake, Raoul S. Concepcion, Daniel W. Lin, Neal D. Shore, Michael B. Williams, Lawrence Karsh, Ken Kernen, Sanjeev Kaul, Charles J. Ryan, Curtis Dunshee, Christopher Michael Pieczonka, Christopher Stewart, Paul Sieber, Kelly L. Stratton
Publikováno v:
The Prostate. 80:1159-1176
Background Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abe0e9d775d02cc3f5047e60006ee6e7
https://doi.org/10.1002/pros.24053
https://doi.org/10.1002/pros.24053
Autor:
John Sylvester, Daniel Saltzstein, Huamao Lin, Yanyan Zhu, Hongliang Shi, Fred Saad, Christopher Michael Pieczonka, Bryan A. Mehlhaff, David P. Dearnaley, Zhan Ye, Lawrence Karsh, David B. MacLean, Neal D. Shore, James Bailen, Hélène M. Faessel
Publikováno v:
European Urology. 78:184-192
External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d745a7dd7e27497b260da7d3e69a0f6f
https://doi.org/10.1016/j.eururo.2020.03.001
https://doi.org/10.1016/j.eururo.2020.03.001
Autor:
Piyush K. Agarwal, Michael A. O’Donnell, Mohamed Hendawi, Matthew Kaag, Simon Hall, Heather Honoré Goltz, Jean H. Hoffman-Censits, Wassim Kassouf, Nihal Mohamed, David M. Latini, Arthur I. Sagalowsky, Sailaja Pisipati, Gary D. Steinberg, Scott M. Gilbert, Diane Zipursky Quale, Cheryl T. Lee, Qainat N. Shah, Tracy M. Downs, Lawrence Karsh, Michael J. Droller
Publikováno v:
BMC Health Services Research, Vol 20, Iss 1, Pp 1-12 (2020)
BMC Health Services Research
BMC Health Services Research
Background, context and purpose In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the feasibility of SCPs in bladder cancer (BC) is sparse. Using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::959caae6ceeb61d74049279991084e9e
http://link.springer.com/article/10.1186/s12913-020-05533-7
http://link.springer.com/article/10.1186/s12913-020-05533-7
Autor:
Huybrecht T’jollyn, Oliver Ackaert, Caly Chien, Angela Lopez-Gitlitz, Sharon McCarthy, Carlos Perez Ruixo, Lawrence Karsh, Kim Chi, Simon Chowdhury, Juan-Jose Perez Ruixo, Neeraj Agarwal
Publikováno v:
Cancer chemotherapy and pharmacology. 89(5)
Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on data from phase 3 TITAN study. This analysis was conducted to describe pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb3dddea28996499f36c2e568fd8480
https://pubmed.ncbi.nlm.nih.gov/35366072
https://pubmed.ncbi.nlm.nih.gov/35366072